1. Home
  2. SILO vs INDP Comparison

SILO vs INDP Comparison

Compare SILO & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

N/A

Current Price

$0.34

Market Cap

4.6M

ML Signal

N/A

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.78

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SILO
INDP
Founded
2010
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.5M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
SILO
INDP
Price
$0.34
$1.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
212.1K
18.0K
Earning Date
05-08-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
0.83
N/A
EPS
N/A
N/A
Revenue
$72,102.00
N/A
Revenue This Year
$1.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.27
52 Week High
$1.23
$13.24

Technical Indicators

Market Signals
Indicator
SILO
INDP
Relative Strength Index (RSI) 49.70 44.31
Support Level $0.33 $1.64
Resistance Level $0.38 $1.99
Average True Range (ATR) 0.03 0.12
MACD 0.00 0.01
Stochastic Oscillator 50.50 36.49

Price Performance

Historical Comparison
SILO
INDP

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: